Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,980.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $10.49, for a total value of $20,980.00. Following the transaction, the president now directly owns 2,901,138 shares in the company, valued at $30,432,937.62. This represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Songjiang Ma also recently made the following trade(s):

• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total transaction of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00.

Gyre Therapeutics Trading Down 2.2 %

GYRE stock opened at $11.48 on Thursday. The company’s 50 day simple moving average is $11.09 and its 200-day simple moving average is $12.57. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $26.37.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds have recently bought and sold shares of the stock. Barclays PLC lifted its position in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares in the last quarter. Geode Capital Management LLC raised its stake in Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. State Street Corp boosted its stake in shares of Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. FMR LLC acquired a new stake in shares of Gyre Therapeutics during the 3rd quarter worth about $47,000. Finally, Advantage Alpha Capital Partners LP purchased a new stake in shares of Gyre Therapeutics during the third quarter worth about $334,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.